Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

Stupp, Roger; Hegi, Monika E; Neyns, Bart; Goldbrunner, Roland; Schlegel, Uwe; Clement, Paul M J; Grabenbauer, Gerhard G; Ochsenbein, Adrian F; Simon, Matthias; Dietrich, Pierre-Yves; Pietsch, Torsten; Hicking, Christine; Tonn, Joerg-Christian; Diserens, Annie-Claire; Pica, Alessia; Hermisson, Mirjam; Krueger, Stefan; Picard, Martin; Weller, Michael (2010). Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. Journal of clinical oncology, 28(16), pp. 2712-8. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2009.26.6650

Full text not available from this repository.

Invasion and migration are key processes of glioblastoma and are tightly linked to tumor recurrence. Integrin inhibition using cilengitide has shown synergy with chemotherapy and radiotherapy in vitro and promising activity in recurrent glioblastoma. This multicenter, phase I/IIa study investigated the efficacy and safety of cilengitide in combination with standard chemoradiotherapy in newly diagnosed glioblastoma.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Ochsenbein, Adrian, Pica, Alessia

ISSN:

0732-183X

Publisher:

American Society of Clinical Oncology

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:09

Last Modified:

05 Dec 2022 14:00

Publisher DOI:

10.1200/JCO.2009.26.6650

PubMed ID:

20439646

Web of Science ID:

000278108800010

URI:

https://boris.unibe.ch/id/eprint/1061 (FactScience: 201786)

Actions (login required)

Edit item Edit item
Provide Feedback